Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19

NCT04410107 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2023-12-04

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus (SARS-CoV-2) that can progress to severe disease requiring hospitalization and oxygen support in around14% of the cases and 5% require admission in intensive care unit. The medium and long-term impact in survivors of severe COVID-19 on lung function, exercise capacity and health-related quality of life remains to be determined.

Conditions

Interventions

DIAGNOSTIC_TEST

Lung Function tests

Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)

DIAGNOSTIC_TEST

Exercise capacity

6-minute walk test (6MWT distance)

DIAGNOSTIC_TEST

Exercise physiology

Cardiopulmonary exercise test (CPET)

DIAGNOSTIC_TEST

Health-related quality of life

Short-Form Health Survey Questionnaire (SF-36)

DIAGNOSTIC_TEST

Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening

1. Adapted translation American Thoracic Society respiratory symptoms questionnaire; 2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI); 3. Questionnaire for screening for post-traumatic stress symptoms (PTSD).

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    collaborator OTHER
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV
  • Hospital Moinhos de Vento

    collaborator OTHER
  • Federal University of Health Science of Porto Alegre

    collaborator OTHER
  • Universidade de Passo Fundo

    collaborator OTHER
  • Hospital Nossa Senhora da Conceicao

    collaborator OTHER
  • Federal University of Rio Grande do Sul

    lead OTHER

Principal Investigators

  • Danilo C Berton, Dr · Universidade Federal do Rio Grande do Sul/Hospital de Clínicas de Porto Alegre

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2023-04-30
Completion
2023-07-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410107 on ClinicalTrials.gov